Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

VIVUS submits avanafil NDA to FDA for treatment of erectile dysfunction

VIVUS, Inc. today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction.

30 Jun 2011

Gene PNPLA3 offers potential therapeutic target in chronic hepatitis C liver damage

New research confirms that a variant on the patatin-like phospholipase-3 (PNPLA3) gene increases risk of steatosis and fibrosis progression in patients with chronic hepatitis C virus (HCV). The PNPLA3 single nucleotide polymorphism (SNP) rs 738409 may represent an important genetic predictor and potential therapeutic target in chronic HCV liver damage.

29 Jun 2011

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.

29 Jun 2011

Positive results from RISE and RIDE Phase III trials of Genentech's Lucentis for diabetic macular edema

Genentech, a member of the Roche Group, today announced 24-month results from the two pivotal Phase III trials (RISE and RIDE) assessing the efficacy and safety of Lucentis (ranibizumab injection) in people with diabetic macular edema (DME).

29 Jun 2011

GABA corrects both known causes of Type 1 diabetes

A chemical produced by the same cells that make insulin in the pancreas prevented and even reversed Type 1 diabetes in mice, researchers at St. Michael's Hospital have found.

29 Jun 2011

U.Va. and Epsilon partner to provide commercial version of computer-based diabetes simulation tool

A computer-based diabetes simulation tool developed by University of Virginia researchers is now commercially available, thanks to a partnership with the Charlottesville-based medical research firm The Epsilon Group. The simulator is the only protocol that has been accepted by the U.S. Food and Drug Administration as an alternative to animal testing of Type 1 diabetes control strategies.

29 Jun 2011

EAS, ESC develop new European guidelines to manage dyslipidaemias

Cardiovascular disease (CVD), driven by the global pandemics of obesity and diabetes, poses a daunting challenge to clinicians in the 21st century. Despite progress, there is still much to be done to improve the control of dyslipidaemia, a key risk factor.

28 Jun 2011

Number of adults with diabetes doubled over past three decades, study shows

The number of adults with type 2 diabetes has doubled worldwide over the last three decades, rising from 153 million in 1980 to 347 million, "a sign that the epidemic will impose an ever-greater cost burden on health systems," according to a study published on Saturday in the Lancet, the Wall Street Journal reports.

28 Jun 2011

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

The American research consortium Type 1 Diabetes TrialNet presented their results of a Phase II study with the antigen-based diabetes therapy Diamyd yesterday, June 27, at the American Diabetes Association 71st Scientific Sessions (ADA) in San Diego, California, USA, after the closing of the stock market.

28 Jun 2011

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.

28 Jun 2011

Very low calorie diet can reverse type 2 diabetes: Study

According to scientists people who have had obesity-related type 2 diabetes for years have been cured, at least temporarily, by keeping to an extreme, low-calorie, diet for two months. The researchers from Newcastle University, overturns previous assumptions about type 2 diabetes, which was thought to be a lifelong illness.

27 Jun 2011

Diabetes numbers on the rise: Experts worried

According a new international study more than 350 million in the world now have diabetes. The analysis, published online by the Lancet on Saturday, adds several tens of millions to the previous estimate of the number of diabetics and indicates that the disease has become a major global health problem.

27 Jun 2011

New and effective diabetes drug seeking approval

A new drug for diabetes from Bristol-Myers Squibb Co. and AstraZeneca PLC was effective in lowering blood sugar. The pharmaceutical drug makers are looking for approval for the drug, dapagliflozin, as the first in new class of pills designed to lower blood sugar by increasing the amount of glucose excreted in the urine.

27 Jun 2011

Lean gene and heart disease risk

According to a new study published Sunday, being lean may not always lead to a lower risk of heart disease and diabetes. The researchers have successfully identified a gene linked both to having a lean body and to a higher risk of metabolic diseases.

27 Jun 2011

Study finds increase in life expectancy for people with type 1 diabetes

The life expectancy of people diagnosed with type 1 diabetes dramatically increased during the course of a 30-year, long-term prospective study, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 71st Scientific Sessions of the American Diabetes Association.

27 Jun 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.

27 Jun 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

Medtronic’s sensor-augmented pump therapy improves outcomes for patients with diabetes

Research presented at the American Diabetes Association's 71st Scientific Sessions (ADA) this week adds to the clinical evidence for Medtronic's sensor-augmented insulin pump therapy for improved glucose control for people with type 1 diabetes.

From Medtronic 27 Jun 2011

Less body fat may increase risk of metabolic diseases

Having a lower percentage of body fat may not always lower your risk for heart disease and diabetes, according to a study by an international consortium of investigators, including two scientists from the Institute for Aging Research of Hebrew SeniorLife, an affiliate of Harvard Medical School (HMS).

27 Jun 2011

Mayo Clinic to create artificial pancreas for treating type 1 diabetes

The 25.8 million Americans who have diabetes may soon be free of finger pricks and daily insulin dosing. Mayo Clinic endocrinologists Yogish Kudva, M.B.B.S., and Ananda Basu, M.B.B.S., M.D., are developing an artificial pancreas that will deliver insulin automatically and with an individualized precision never before possible.

27 Jun 2011